Results 271 to 280 of about 98,896 (358)

The Secretome of Bullous Pemphigoid IgG‐Treated Keratinocytes Induces a Pro‐Inflammatory Eosinophil Response

Experimental Dermatology, Volume 35, Issue 5, May 2026.
ABSTRACT Bullous pemphigoid (BP) is an autoimmune blistering disease whereby the cutaneous antigens BP180 and BP230 are targeted by autoantibodies. Skin lesions in BP are characterized by an abundance of eosinophils. We recently demonstrated that the treatment of keratinocytes with antibodies from patients with BP induces a robust inflammatory response
Adrian P. Mansini, Lei Bao, Krishan D. Chhiba, Jing Li, Yulu Wang, Haley Gainer, M. Allen McAlexander, Christopher McCrae, Christopher D. Nazaroff, Fei Li Kuang, Kyle T. Amber   +10 more
wiley   +1 more source

Editorial: Exploring sulfur compounds' role in inflammation and therapeutic potential. [PDF]

Front Immunol
Iciek M, Sawa T, Lauriano ER, Kotańska M.   +3 more
europepmc   +1 more source

Global consensus on the management of melanin hyperpigmentation disorders

Journal of the European Academy of Dermatology and Venereology, Volume 40, Issue 5, Page 760-772, May 2026.
A global Delphi consensus of 10 dermatology experts established evidence‐based recommendations for melanin hyperpigmentation disorders, providing unified classification, photoprotection guidance and treatment algorithms. This framework harmonizes terminology and supports individualized management across diverse skin types and health systems.
Thierry Passeron, Seemal R. Desai, Marwa Abdallah, Firas Al‐Niaimi, Ncoza Dlova, Pearl E. Grimes, Jorge Ocampo‐Candiani, Rashmi Sarkar, Leihong Flora Xiang, Helio Amante Miot   +9 more
wiley   +1 more source

Effect of leukotriene receptor antagonist use on the future risk of Parkinson's disease in older patients with asthma. [PDF]

Brain Commun
Ju C, Chen B, Schrag A, Carroll C, Foltynie T, Wei L.   +5 more
europepmc   +1 more source

Pharmacokinetics and Anti‐Inflammatory Effects of Intramuscular Betamethasone in Exercised Thoroughbred Horses

Journal of Veterinary Pharmacology and Therapeutics, Volume 49, Issue 3, Page 295-305, May 2026.
ABSTRACT The pharmacokinetics and pharmacodynamics of betamethasone following intra‐articular administration to horses have been described; however, studies characterizing intramuscular administration are lacking. Twenty‐four horses received an intramuscular dose of 12 mg betamethasone sodium phosphate/betamethasone acetate.
Juliana Sullivan, Jeff Blea, Daniel S. McKemie, Philip H. Kass, Heather K. Knych   +4 more
wiley   +1 more source

Glycolytic-Cholesterol Subtypes of Severe Asthma Reveal Distinct Immune-Inflammatory and Metabolic Phenotypes. [PDF]

J Inflamm Res
Lin Q, Ni H, Zhang J, Xu T.
europepmc   +1 more source

Acupuncture‐Integrated Chinese‐Western Medicine Accelerated Rehabilitation Protocol Following Acute Achilles Tendon Repair: A Prospective Cohort Study

Orthopaedic Surgery, Volume 18, Issue 5, Page 1054-1064, May 2026.
This study demonstrates that acupuncture‐integrated accelerated rehabilitation after acute Achilles tendon repair significantly reduces early postoperative pain and swelling, facilitating mobilization and enhancing objective functional recovery at 12 weeks compared to traditional and sham acupuncture protocols. ABSTRACT Objective Postoperative pain and
Gao Si, Chi Zhang, Xiuzhi Li, Yuan Cao, Zengzhen Cui, Jingying Li, Letian Wang, Yang Lv, Dong Li   +8 more
wiley   +1 more source

Heat-treated egg allergens show lower basophil activation: A path toward safer oral immunotherapy. [PDF]

Pediatr Allergy Immunol
Paolucci M, Breiding M, Dietrich M, Meyer JG, Duda A, Köhli A, Lang CCV, Agah S, Wuenschmann S, Eyer K, Kündig TM, Trück J, Johansen P.   +12 more
europepmc   +1 more source

Characteristics and outcomes of patients with pediatric‐onset non‐mastocytosis mast cell activation disorders: A CEREMAST study

Pediatric Allergy and Immunology, Volume 37, Issue 5, May 2026.
Abstract Background Mast cell (MC) activation (MCA) disorders (MCAD) include diseases in which MCs excessively release mediators leading to recurrent manifestations of MCA. MCAD encompasses MCA syndrome (MCAS) which is defined by (i) documented systemic symptoms of MCA, (ii) a 20% increase in serum tryptase level from the individual's baseline plus 2 ...
M. Weiss, J. Rossignol, F. Campeotto, E. Foy, C. Elbany, L. Jaume, L. Geroux, O. Debeaupuis, A. Neuraz, L. Bekel, G. Lezmi, N. Bellon, C. Méni, C. Livideanu, M. Madrange, D. Condé, J. Agopian, C. Michot, F. Villard‐Truc, A. Lachaux, C. Greco, S. Hadj‐Rabia, P. Dubreuil, O. Hermine, C. Bodemer, L. Polivka   +25 more
wiley   +1 more source